SPRY3

Summary

SPRY3 (sprouty RTK signaling antagonist 3, HGNC:11271) is a protein-coding gene on chromosome Xq28 and Yq12, encoding Protein sprouty homolog 3 (O43610). Inhibits neurite branching, arbor length and neurite complexity.

Involved in negative regulation of MAPK cascade. Predicted to be located in cytoplasm and membrane. Predicted to be active in cytosol.

Source: NCBI Gene 10251 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 153 total
• MANE Select transcript: NM_001304990

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11271
Approved symbol	SPRY3
Name	sprouty RTK signaling antagonist 3
Location	Xq28 and Yq12
Locus type	gene with protein product
Status	Approved
Aliases	HSPRY3
Ensembl gene	ENSG00000168939
Ensembl biotype	protein_coding
OMIM	300531
Entrez	10251

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000302805, ENST00000675360, ENST00000676089, ENST00000695325, ENST00000902799, ENST00000902800, ENST00000929615, ENST00000929616

RefSeq mRNA: 5 — MANE Select: NM_001304990 NM_001304990, NM_001394353, NM_001394354, NM_001394355, NM_005840

CCDS: CCDS14769

Canonical transcript exons

ENST00000695325 — 3 exons

Exon	Start	End
ENSE00003963428	155767962	155768136
ENSE00003963429	155612586	155612647
ENSE00003963430	155773766	155782459

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 81.29.

FANTOM5 (CAGE): breadth broad, TPM avg 1.0163 / max 41.5144, expressed in 604 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
198219	1.0163	604

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	81.29	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.26	gold quality
cortical plate	UBERON:0005343	73.03	gold quality
tibialis anterior	UBERON:0001385	71.37	silver quality
right hemisphere of cerebellum	UBERON:0014890	70.65	gold quality
cerebellar cortex	UBERON:0002129	70.53	gold quality
cerebellar hemisphere	UBERON:0002245	70.51	gold quality
embryo	UBERON:0000922	70.25	gold quality
ganglionic eminence	UBERON:0004023	70.25	gold quality
cerebellum	UBERON:0002037	69.31	gold quality
ileal mucosa	UBERON:0000331	68.84	silver quality
adrenal tissue	UBERON:0018303	68.12	gold quality
bone marrow cell	CL:0002092	67.85	silver quality
ventricular zone	UBERON:0003053	67.53	gold quality
prefrontal cortex	UBERON:0000451	66.77	gold quality
right adrenal gland cortex	UBERON:0035827	66.06	gold quality
gastrocnemius	UBERON:0001388	66.02	gold quality
muscle of leg	UBERON:0001383	65.81	gold quality
stromal cell of endometrium	CL:0002255	65.74	gold quality
descending thoracic aorta	UBERON:0002345	64.50	gold quality
left adrenal gland	UBERON:0001234	64.43	gold quality
right adrenal gland	UBERON:0001233	64.31	gold quality
hindlimb stylopod muscle	UBERON:0004252	64.27	gold quality
colonic epithelium	UBERON:0000397	64.05	silver quality
left adrenal gland cortex	UBERON:0035825	63.92	gold quality
adrenal gland	UBERON:0002369	63.63	gold quality
adrenal cortex	UBERON:0001235	62.69	gold quality
smooth muscle tissue	UBERON:0001135	62.57	gold quality
thoracic aorta	UBERON:0001515	61.97	gold quality
deltoid	UBERON:0001476	61.91	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

359 targeting SPRY3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-103A-3P	99.98	69.14	1595

Literature-anchored findings (GeneRIF, showing 5)

• Spry 1, 2 and 3 expression was observed in placental tissue from all three trimesters (PMID:15950061)
• the Sprouty/Caveolin-1 interaction modulates signaling in a growth factor- and Sprouty isoform-specific manner (PMID:16877379)
• SPRY3 is a candidate susceptibility locus for autism and related or over-lapping disorders such as ataxia. (PMID:26089202)
• The authors presented the data that Spry3 potentiates the tumorigenic potential of glioblastoma cells. (PMID:31374860)
• Sprouty3, but Not Sprouty1, Expression Is Beneficial for the Malignant Potential of Osteosarcoma Cells. (PMID:34769378)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
rattus_norvegicus	Spry3	ENSRNOG00000060153
rattus_norvegicus	Spry3-ps1	ENSRNOG00000064505
drosophila_melanogaster	sty	FBGN0014388

Paralogs (3): SPRY2 (ENSG00000136158), SPRY1 (ENSG00000164056), SPRY4 (ENSG00000187678)

Protein

Protein identifiers

Protein sprouty homolog 3 — O43610 (reviewed: O43610)

Alternative names: Sprouty RTK signaling antagonist 3, Sprouty3

All UniProt accessions (1): O43610

UniProt curated annotations — full annotation on UniProt →

Function. Inhibits neurite branching, arbor length and neurite complexity. Inhibits EGF-mediated p42/44 ERK signaling. Negatively regulates the MAPK cascade, resulting in a reduction of extracellular matrix protein accumulation. May function as an antagonist of fibroblast growth factor (FGF) pathways and may negatively modulate respiratory organogenesis.

Subunit / interactions. Interacts with TESK1. Interacts with USP11. Interacts with CAV1 (via C-terminus).

Subcellular location. Cytoplasm.

Tissue specificity. Widely expressed; particularly in the fetal tissues. Expressed in the brain with expression the highest in Purkinje cells in the cerebellum (at protein level). Expressed in the myocardium of the heart.

Induction. By FGF signaling. Repressed by microRNA-143-3P, which results in activation of MAPK signaling and promotion of excess accumulation of extracellular matrix. May thereby play a role in myocardial fibrosis.

Miscellaneous. The gene coding for this protein is located in the pseudoautosomal region 2 (PAR2) of X and Y chromosomes.

Similarity. Belongs to the sprouty family.

RefSeq proteins (5): NP_001291919, NP_001381282, NP_001381283, NP_001381284, NP_005831 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007875	Sprouty	Family
IPR051192	Sprouty_domain	Family

Pfam: PF05210

UniProt features (4 total): chain 1, domain 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O43610-F1	63.71	0.21

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 153 (showing top): GOBP_NEGATIVE_REGULATION_OF_ERK1_AND_ERK2_CASCADE, GOBP_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_NEGATIVE_REGULATION_OF_ERBB_SIGNALING_PATHWAY, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_NEUROGENESIS, GOBP_NEGATIVE_REGULATION_OF_MAPK_CASCADE, GOBP_NEGATIVE_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_NEGATIVE_REGULATION_OF_FIBROBLAST_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_RESPONSE_TO_GROWTH_FACTOR_STIMULUS, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_ERBB_SIGNALING_PATHWAY

GO Biological Process (9): nervous system development (GO:0007399), negative regulation of fibroblast growth factor receptor signaling pathway (GO:0040037), negative regulation of MAPK cascade (GO:0043409), negative regulation of Ras protein signal transduction (GO:0046580), animal organ development (GO:0048513), negative regulation of ERK1 and ERK2 cascade (GO:0070373), negative regulation of neuron projection arborization (GO:0150013), multicellular organism development (GO:0007275), regulation of signal transduction (GO:0009966)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (3): cytosol (GO:0005829), membrane (GO:0016020), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
anatomical structure development	2
system development	1
fibroblast growth factor receptor signaling pathway	1
negative regulation of signal transduction	1
regulation of fibroblast growth factor receptor signaling pathway	1
negative regulation of cellular response to growth factor stimulus	1
MAPK cascade	1
regulation of MAPK cascade	1
negative regulation of intracellular signal transduction	1
Ras protein signal transduction	1
regulation of Ras protein signal transduction	1
negative regulation of small GTPase mediated signal transduction	1
negative regulation of MAPK cascade	1
ERK1 and ERK2 cascade	1
regulation of ERK1 and ERK2 cascade	1
negative regulation of cell projection organization	1
negative regulation of developmental process	1
neuron projection arborization	1
regulation of neuron projection arborization	1
multicellular organismal process	1
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
binding	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

622 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SPRY3	VAMP7	P51809	784
SPRY3	IL9R	Q01113	756
SPRY3	SPARC	P09486	648
SPRY3	FGF8	P55075	643
SPRY3	FGF6	P10767	620
SPRY3	PLCXD1	Q9NUJ7	580
SPRY3	ASMTL	O95671	542
SPRY3	DHRSX	Q8N5I4	541
SPRY3	FGF18	O76093	529
SPRY3	FGF20	Q9NP95	528
SPRY3	TMLHE	Q9NVH6	528
SPRY3	FGF10	O15520	526
SPRY3	FGF16	O43320	525
SPRY3	FGF22	Q9HCT0	514
SPRY3	FGF5	P12034	507

IntAct

82 interactions, top by confidence:

A	B	Type	Score
SPRY3	MEOX2	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	GPSM3	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	NEK6	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	LCE3E	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	KPRP	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	BEX2	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	SLC39A7	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	LCE1F	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	LCE3D	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	CHRD	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	ZNF587	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	KRT34	psi-mi:“MI:0915”(physical association)	0.560
LCE2B	SPRY3	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	ZDHHC17	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	CATSPER1	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	VSNL1	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	R3HDM2	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	LCE3A	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	CREB5	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	LCE1A	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	LCE1B	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	AQP1	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	HOXA1	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	GNE	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	MAPKBP1	psi-mi:“MI:0915”(physical association)	0.560
HR	SPRY3	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	ZNF655	psi-mi:“MI:0915”(physical association)	0.560
SPRY3	MEOX2	psi-mi:“MI:0915”(physical association)	0.000
GPSM3	SPRY3	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (30): SPRY3 (Positive Genetic), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid), SPRY3 (Two-hybrid)

ESM2 similar proteins: A0A1B0GVS7, A2CE83, A2VDU1, A5D992, A8KBE0, O43597, O43609, O43610, P28290, Q02223, Q08AD1, Q08E39, Q14CH0, Q1L0X2, Q2PFN5, Q2TBG9, Q3UUD2, Q4R815, Q5R959, Q5RGQ8, Q5TB30, Q66H35, Q6AYK4, Q6DD45, Q6GPM0, Q6NRB7, Q6P995, Q6PEM6, Q6ZUJ8, Q7ZX27, Q866R9, Q86VY9, Q8BGN6, Q8C3K5, Q8C817, Q8IYD9, Q8N957, Q96HH4, Q9BZD6, Q9C004

Diamond homologs: A2VDU1, A5D992, O43597, O43609, O43610, O44783, Q08E39, Q1L0X2, Q2MJR0, Q2PFN5, Q3C2P8, Q3UUD2, Q5R959, Q5RDN2, Q5Y171, Q6NYK3, Q6P6N5, Q7Z698, Q7Z699, Q866R9, Q924S7, Q924S8, Q9C004, Q9PTL1, Q9PTL2, Q9QXV8, Q9QXV9, Q9WTP2, Q66JG9, P50551, O08719, P50552, P70429, P70460, Q03173, Q2TA49, Q64GL0, Q8N8S7, Q8T4F7, Q5R896

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 27 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of the cornified envelope	8	39.0×	3e-10
Keratinization	8	24.8×	6e-09

GO biological processes:

GO term	Partners	Fold	FDR
keratinization	7	63.0×	2e-09

Disease & clinical

Clinical variants and AI predictions

ClinVar

153 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	3
Likely benign	0
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

412 predictions. Top by Δscore:

Variant	Effect	Δscore
X:155769530:GATT:G	donor_gain	1.0000
X:155612787:CCCA:C	donor_loss	0.9900
X:155612788:CCAC:C	donor_loss	0.9900
X:155612789:CACCT:C	donor_loss	0.9900
X:155612790:A:C	donor_loss	0.9900
X:155612791:CCTG:C	donor_loss	0.9900
X:155768135:AGGTA:A	donor_loss	0.9900
X:155768137:G:GA	donor_loss	0.9900
X:155768138:T:G	donor_loss	0.9900
X:155768137:G:GG	donor_gain	0.9700
X:155769480:G:GG	donor_gain	0.9700
X:155774699:T:TA	donor_gain	0.9700
X:155774700:A:AA	donor_gain	0.9700
X:155612474:CA:C	donor_gain	0.9500
X:155612790:A:AC	donor_gain	0.9500
X:155612791:C:CC	donor_gain	0.9500
X:155769496:G:GT	donor_gain	0.9500
X:155769482:AG:A	donor_gain	0.9400
X:155769481:T:TA	donor_gain	0.9300
X:155769529:GGATT:G	donor_gain	0.9300
X:155769479:A:G	donor_gain	0.9200
X:155769486:C:G	donor_gain	0.8900
X:155612522:T:TA	donor_gain	0.8800
X:155774753:G:GA	donor_gain	0.8700
X:155773760:TCCTA:T	acceptor_loss	0.8600
X:155773761:CCTA:C	acceptor_loss	0.8600
X:155773762:CTA:C	acceptor_loss	0.8600
X:155773763:TAGGA:T	acceptor_loss	0.8600
X:155773764:A:C	acceptor_loss	0.8600
X:155773765:G:GA	acceptor_loss	0.8600

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000029487 (X:155777418 C>A,G,T), RS1000050113 (X:155645623 C>G,T), RS1000149416 (X:155732589 G>A), RS1000163025 (X:155674620 A>G), RS1000175225 (X:155762314 G>C,T), RS1000202744 (X:155703928 G>A,T), RS1000222583 (X:155707907 A>G), RS1000270220 (X:155761864 G>T), RS1000333657 (X:155696747 G>A), RS1000337227 (X:155748111 C>G), RS1000443833 (X:155708307 G>A,C), RS1000447719 (X:155754714 A>G), RS1000480613 (X:155772519 C>T), RS1000495446 (X:155721621 G>A,C,T), RS1000504152 (X:155740521 T>C)

Disease associations

OMIM: gene MIM:300531 | disease phenotypes: MIM:300872

GenCC curated gene-disease

Mondo (2): epsilon-trimethyllysine hydroxylase deficiency (MONDO:0010469), ependymoma (MONDO:0016698)

Orphanet (1): Ependymoma (Orphanet:251636)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST003918_2	Idiopathic osteonecrosis of the femoral head	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:1001930	idiopathic osteonecrosis of the femoral head

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D004806	Ependymoma	C04.557.465.625.600.380.290; C04.557.470.670.380.290; C04.557.580.625.600.380.290

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

10 total (human), top 10 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
sodium arsenite	decreases expression	1
nickel sulfate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	increases reaction, affects binding	1
Sunitinib	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Particulate Matter	decreases expression	1

Clinical trials (associated diseases)

95 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00517959	PHASE3	UNKNOWN	SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors
NCT01096368	PHASE3	COMPLETED	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
NCT00003479	PHASE2	TERMINATED	Antineoplaston Therapy in Treating Patients With Ependymoma
NCT00520936	PHASE2	COMPLETED	A Study of Pemetrexed in Children With Recurrent Cancer
NCT00840047	PHASE2	ACTIVE_NOT_RECRUITING	Methionine PET/CT Studies In Patients With Cancer
NCT01088035	PHASE2	TERMINATED	Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma
NCT01247922	PHASE2	TERMINATED	Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
NCT01288235	PHASE2	COMPLETED	Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
NCT01295944	PHASE2	COMPLETED	Carboplatin and Bevacizumab for Recurrent Ependymoma
NCT01356290	PHASE2	RECRUITING	Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
NCT01836549	PHASE2	TERMINATED	Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
NCT02125786	PHASE2	ACTIVE_NOT_RECRUITING	A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma
NCT02689336	PHASE2	WITHDRAWN	Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors
NCT03095248	PHASE2	TERMINATED	Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
NCT03155620	PHASE2	ACTIVE_NOT_RECRUITING	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
NCT03173950	PHASE2	COMPLETED	Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
NCT03194906	PHASE2	COMPLETED	Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors
NCT03210714	PHASE2	ACTIVE_NOT_RECRUITING	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213652	PHASE2	ACTIVE_NOT_RECRUITING	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
NCT03213665	PHASE2	COMPLETED	Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
NCT03213678	PHASE2	COMPLETED	Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
NCT03213704	PHASE2	ACTIVE_NOT_RECRUITING	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
NCT03220035	PHASE2	COMPLETED	Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
NCT03233204	PHASE2	COMPLETED	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03526250	PHASE2	COMPLETED	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
NCT03698994	PHASE2	ACTIVE_NOT_RECRUITING	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
NCT03727841	PHASE2	TERMINATED	Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
NCT04049669	PHASE2	ACTIVE_NOT_RECRUITING	Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04195555	PHASE2	ACTIVE_NOT_RECRUITING	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
NCT04284774	PHASE2	ACTIVE_NOT_RECRUITING	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04320888	PHASE2	ACTIVE_NOT_RECRUITING	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
NCT04374305	PHASE2	RECRUITING	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
NCT04743661	PHASE2	ACTIVE_NOT_RECRUITING	131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
NCT06804655	PHASE2	NOT_YET_RECRUITING	Pharmacoscopy for Patients With Refractory Primary Brain Tumors
NCT07424092	PHASE2	RECRUITING	Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors
NCT00634231	PHASE1	COMPLETED	A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
NCT00994071	PHASE1	COMPLETED	A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
NCT01171469	PHASE1	COMPLETED	Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
NCT01331135	PHASE1	COMPLETED	Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors
NCT01498783	PHASE1	COMPLETED	Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma